‘EXPLORING GROWTH OPPORTUNITIES WITH SPUTNIK VACCINE’

“As of now, we have commercialised the Sputnik vaccine, Favipiravir under the brand name Avigan, Remdesivir and 2DG. We’re going to conduct clinical trials for Molnupiravir and various other drugs. While this portfolio has made a decent contribution in the last few quarters, we believe that there are multiple opportunities even for the future. Specific to Sputnik, we are exploring several growth opportunities which include (a) Sputnik Light as a vaccine or as a booster dose, (b) Sputnik Light for adolescents, and (c) export opportunities. We are also investing in various innovation businesses, which will provide growth in the long term. This includes building a global pipeline of biosimilar, developments of NCE for immune-oncology, building up of a nutraceutical portfolio, vaccines, CDMO and digital healthcare platforms.”

- EREZ ISRAELI,

Chief Executive Officer, Dr. Reddy’s Laboratories, Hyderabad